Friday, 23 January 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 23 January 2026
News

More insulin products to be axed

Posted 21 January 2026 AM

Eli Lilly has joined Novo Nordisk in discontinuing some of its own insulin products from the Australian market, with the latter also providing an update on the availability of its insulin offerings.

The vial presentations of Lilly’s Humalog, Humulin R vials, Humulin NPH, and Humulin 30/70 are set to be discontinued from August. Alternative presentations of these insulins are expected to remain available, including KwikPen and cartridge dose forms.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (13)

Access & Reimbursement (1)

Clinical & Medical, R&D (4)

Regulatory, Pharmacovigilance & QA (5)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.